Multi-strain formulation – What’s the importance?

When scientists first studied the human microbiota, 400 different species were isolated. To this day, more than 1,000 species have been recorded.1

The human body naturally contains a diverse variety of strains, as such, choosing a multi-strain formulation such as HEXBIO®, where Lactobacilli and Bifidobacteria are present, may represent the best choice for good health.

 

Multiple strains can have synergistic effects.

 

Each strain have different functions and exerts different health benefits. A formulation of several high-quality strains will provide a wider range of immune support and effects because of the important synergy between the strains.

Scientists have examined studies that looked at the effects of single and multi-strain products, and found that there seemed to be a trend towards better clinical results with multi-strain formulations.2 In a recent meta-analysis of research, scientists suggest that multi-strain formulations have been highly effective at alleviating certain gut conditions, while boosting overall gut and immune functions, which means that they may be the simplest and most effective overall strategy.3

 

What is truly important is the quality and safety of the microbial cell strains – strains that have shown clinical efficacy in clinical studies.

 

6 specific strains of Lactobacilli and Bifidobacteria, marketed as HEXBIO®, is at the forefront of microbial cell research and product development. HEXBIO® is a science-backed multi-strain microbial cell preparation (MCP) that is proven safe and effective.

Moreover, the HEXBIO® MCP strains are supported by peer-reviewed, published clinical studies and has been shown to be effective to address gut symptoms and supporting immune function.4, 5, 6, 7 These clinical trials are randomized, double- blinded and placebo-controlled studies, which are often considered “gold standard” or most reliable evidence.

It’s important to always remember that research is with strain-specific formulation, and any success with one formulation may not translate to another.

At B-Crobes, we take pride in the science-supported formulations we develop with our customers. HEXBIO® is a multi-strain MCP that offers many clinically-proven health benefits including digestive and immune utilization support. To learn more about HEXBIO®, visit: https://bcrobes.com/hexbio/

 

References

  1. Ursell, L. K., Haiser, H. J., Van Treuren, W., Garg, N., Reddivari, L., Vanamala, J., … & Knight, R. (2014). The intestinal metabolome: an intersection between microbiota and host. Gastroenterology, 146(6), 1470-1476.
  2. Chapman, C. M. C., Gibson, G. R., & Rowland, I. (2011). Health benefits of probiotics: are mixtures more effective than single strains?. European journal of nutrition, 50(1), 1-17
  3. Chang, H. Y., Chen, J. H., Chang, J. H., Lin, H. C., Lin, C. Y., & Peng, C. C. (2017). Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis. PLoS One, 12(2), e0171579.
  4. Jayasimhan, S., Yap, N. Y., Roest, Y., Rajandram, R., & Chin, K. F. (2013). Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial. Clinical nutrition, 32(6), 928-934.
  5. Malik, A. A., Rajandram, R., Tah, P. C., Hakumat-Rai, V. R., & Chin, K. F. (2016). Microbial cell preparation in enteral feeding in critically ill patients: A randomized, double-blind, placebo-controlled clinical trial. Journal of critical care, 32, 182-188.
  6. Tan, C. K., Said, S., Rajandram, R., Wang, Z., Roslani, A. C., & Chin, K. F. (2016). Pre-surgical administration of microbial cell preparation in colorectal cancer patients: a randomized controlled trial. World journal of surgery, 40(8), 1985-1992.
  7. Golkhalkhali, B., Rajandram, R., Paliany, A. S., Ho, G. F., Ishak, W., Zamaniah, W., … & Chin, K. F. (2017). Strain‐specific probiotic (microbial cell preparation) and omega‐3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: A randomized controlled trial. Asia‐Pacific Journal of Clinical Oncology.
By | 2018-10-05T03:38:07+00:00 October 5th, 2018|Health Articles|0 Comments

About the Author:

Leave A Comment

Translate »